As the pharmaceutical industry advances into a new era of precision therapeutics, molecular modification technologies are emerging as critical tools to enhance drug pharmacokinetics, safety, and delivery efficiency. Litchlab is proud to announce the full launch of its next-generation "Precision PEGylation Platform", providing global clients with a comprehensive, modular solution that spans from site selection and conjugation chemistry to process optimization and scale-up production.
Polyethylene glycol (PEG) conjugation—commonly known as PEGylation—has long been used to extend circulation half-life, improve solubility, reduce immunogenicity, and enable targeted drug delivery. However, conventional PEGylation methods often suffer from inconsistent modification sites and uncontrolled molecular behavior, leading to reduced bioactivity or batch variability.
Litchlab’s Precision PEGylation Platform overcomes these challenges with cutting-edge site-specific conjugation chemistry, structural PEG customization, and high-throughput analytical tools, setting a new benchmark for the industry.
Leveraging enzyme-assisted ligation, orthogonal chemistry, and engineered amino acid motifs, Litchlab enables precise modification at predetermined residues (e.g., cysteine, ketone, or aldehyde sites) to ensure batch uniformity and functional retention.
✅ Applicable to monoclonal antibodies, antibody fragments, enzymes, fusion proteins, vaccines, and more.
Supports linear PEG, branched PEG, 4-arm PEG, and star-shaped PEG structures ranging from 2 kDa to 80 kDa.
✅ Tailored for specific tissue targeting, receptor engagement, and endosomal escape profiles.
Validated for a diverse pipeline of molecules:
Monoclonal & bispecific antibodies (mAbs, bsAbs)
mRNA, siRNA, and antisense oligonucleotides (ASOs)
Peptides, proteins, and immunogens
Linkers and carriers for ADC/RDC systems
PEGylation reduces enzymatic degradation and enhances in vivo stability, supporting long-acting release and deep-tissue targeting, including tumors, lungs, and the brain (BBB penetration).
Litchlab’s platform is equipped with:
LC-MS/MS and MALDI-TOF for site occupancy analysis
SEC-HPLC and GPC for PEG chain distribution
DLS and zeta potential for size/stability tuning
In vitro bioactivity and release assays
The rise of biologics, RNA therapeutics, and targeted drug conjugates has significantly increased the demand for optimized delivery systems. PEGylation is no longer a convenience—it is a regulatory and therapeutic imperative. According to EvaluatePharma, the global PEGylated therapeutics market is projected to exceed $15 billion by 2030, with major traction in oncology, immunology, rare diseases, and ophthalmology.
Amid growing CMC complexity and regulatory expectations, pharma and biotech firms are actively seeking CDMO partners with deep expertise in site-selective PEGylation and scalable manufacturing, especially for IND- and BLA-stage programs.
mRNA-LNP surface PEGylation to modulate immune recognition and prolong circulation
Tumor-targeted PEGylated fusion proteins with site-specific linkers for improved pharmacodynamics
PEGylated BBB-penetrating ADC carriers, enhancing delivery across the blood-brain barrier
siRNA-PEG conjugates optimized for systemic delivery and stability in plasma
“Precision PEGylation is one of the most strategic enablers of next-generation biologics,”
said Dr. Q. Zhang, Head of Conjugation Technologies at Litchlab.
“It bridges molecule design and clinical performance in ways few technologies can match.”
Litchlab is a global CDMO innovator specializing in drug delivery platforms, molecular modification technologies, and complex formulation development. Its capabilities span lipid nanoparticles, liposomes, hydrogels, antibody-drug conjugates (ADCs), receptor-drug conjugates (RDCs), and advanced PEGylation systems.
The company supports partners from early-stage discovery to clinical manufacturing, offering integrated services with global regulatory compliance and robust analytical infrastructure.
To collaborate on PEGylation strategies or learn more about Litchlab’s CDMO services:
🔗 Visit: www.litchlab.com
📧 Contact: RD1@litchlab.com
